Filtered By:
Drug: Medroxyprogesterone
Therapy: Endocrine Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Alopecia With Endocrine Therapies in Patients With Cancer.
CONCLUSION: Alopecia is a common yet underreported adverse event of endocrine-based cancer therapies. Their long-term use heightens the importance of this condition on patients' quality of life. These findings are critical for pretherapy counseling, the identification of risk factors, and the development of interventions that could enhance adherence and mitigate this psychosocially difficult event.
PMID: 24037977 [PubMed - as supplied by publisher]
Source: The Oncologist - September 13, 2013 Category: Cancer & Oncology Authors: Saggar V, Wu S, Dickler MN, Lacouture ME Tags: Oncologist Source Type: research
